Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Clinical Trial ID NCT00374322

PubWeight™ 13.38^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00374322

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nat Rev Clin Oncol	2011	4.12
2	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.	Lancet Oncol	2012	1.75
3	Treatment of HER2-positive breast cancer.	Breast	2013	1.09
4	Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.	J Clin Oncol	2014	0.94
5	Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.	Int J Breast Cancer	2012	0.92
6	Lapatinib for advanced or metastatic breast cancer.	Oncologist	2012	0.82
7	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.	Breast Cancer Res	2015	0.81
8	Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.	Pharmacogenomics J	2015	0.80
9	Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer.	Breast Cancer (Dove Med Press)	2012	0.79
10	Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.	Jpn J Clin Oncol	2010	0.79
11	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.	Ther Adv Med Oncol	2016	0.75
12	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.	Eur J Cancer	2015	0.75